Mylan CEO sees faster drug approvals, cheaper generics with FDA Chief Gottlieb - (FOX Business via NewsPoints Desk)

  • Mylan CEO Heather Bresch said that the pace of generic drug approvals has increased under FDA Commissioner Scott Gottlieb, Fox Business reported Tuesday.

  • The drugmaker, which received approval for a generic version of Teva's multiple sclerosis drug Copaxone in October 2017, expects support for its generic version of GlaxoSmithKline's Advair.

  • The news comes as Mylan is attempting to recover from controversy over the price of the allergy drug EpiPen.

  • The drugmaker agreed to pay $465 million last year to the US Department of Justice to resolve claims that the company overcharged the government for the drug.

  • Bresch suggested that price gouging remains a major issue in the pharmaceutical sector.

  • "It's at a terrible inflection point and it's not sustainable," Bresch stated, adding "every pharmaceutical company is negotiating and paying rebates into the system and the problem is they are not translated…they are not being transferred to that patient."

  • FirstWord Reports: Providing insight, analysis and expert opinion on important Pharma trends and challenging issues <Click here>

To read more NewsPoints articles, click here.